

1 **Supporting Information**


2  
3 **Dimerization of human uridine diphosphate glucuronosyltransferase**  
4 **allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities**

5  
6  
7 **Yan-Qing Liu<sup>†</sup>, Ling-Min Yuan<sup>†</sup>, Zhang-Zhao Gao, Yong-Sheng Xiao, Hong-Ying Sun,**  
8 **Lu-Shan Yu<sup>\*</sup> & Su Zeng<sup>\*</sup>**

9  
10 *Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key*  
11 *Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang*  
12 *University, Hangzhou 310058, China*

13  
14 <sup>†</sup> These authors contributed equally to the work reported in this manuscript.

15  
16  
17  
18 <sup>\*</sup> Corresponding author: Lushan Yu, Associate Professor. Address: College of  
19 Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Tel: +86 571 88208407;  
20 fax: +86 571 88208407; E-mail: yuls@zju.edu.cn; Su Zeng, Professor. Address: College of  
21 Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Tel: +86 571 88208405;  
22 fax: +86 571 88208405; E-mail: zengsu@zju.edu.cn



25

26 **Figure S1. Fluorescence by each UGT1A-CFP and UGT1A-YFP fusion protein in Sf9**

27 **cells.** Sf9 cells infected with recombinant UGT1A1\*1-CFP/YFP *Baculovirus* (A),

28 UGT1A1\*1b-CFP/YFP *Baculovirus* (B), UGT1A9\*1-CFP/YFP *Baculovirus* (C),


29 UGT1A9\*2-CFP/YFP *Baculovirus* (D), UGT1A9\*3-CFP/YFP *Baculovirus* (E) and

30 UGT1A9\*5-CFP/YFP *Baculovirus* (F). The CFP-tagged proteins were only clearly visible in

31 the CFP channel with no bleed-through in the YFP channel. Conversely, YFP-tagged proteins

32 were only clearly visible in the YFP channel.

33



34


35 **Figure S2. The anti-HA beads specifically immunoprecipitated with the HA-tagged**

36 **allozyme proteins.** To monitor the specificity of the proteins immunoprecipitated with the

37 anti-HA beads, Sf9 cells were transfected with either UGT1A1\*N-HA(56 kDa)/CFP (81 kDa)


38 (A) recombinant virus or UGT1A9\*N-HA (56 kDa) /CFP (81 kDa) (B) recombinant virus.

39



40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Figure S3. The expression levels of UGT1A allozymes in the single- and double-expression systems.** The expression levels of UGT1A1\*N (AD) and UGT1A9\*N (F–I) proteins were determined by immunoblot analysis. The total cell homogenates from Bac-to-Bac expression systems (2 to 8 μg for UGT1A1 and 0.8 to 16 μg for UGT1A9) were subjected to 10% SDS-PAGE and the membranes were probed with anti-UGT1A antibody. The relative expressions were measured using Quantity One 1-D analysis software (E and J). Columns are the mean ± standard deviation (SD) from three independent determinations.



50

51 **Figure S4. Representative high-pressure liquid chromatography (HPLC)**

52 **chromatograms of quercetin incubated with UGT1A1\*1-HA and UGT1A9\*1-HA. The**

53 **reaction mixture consisted of a total volume of 100  $\mu$ L containing Tris-HCl (pH = 7.4, 0.1 M),**

54 **MgCl<sub>2</sub> (10 mM), UDPGA (5 mM), alamethicin (50  $\mu$ g/mg of protein), total cell homogenates**

55 **expressing UGT1A1\*1-HA or UGT1A9\*1-HA (1 mg/mL), and quercetin (0.1 mM). The**

56 **incubation time was 30 min. Quercetin was mainly converted into M1, M3, and M4 by**


57 **UGT1A1 (A) and M1, M2, and M4 by UGT1A9 (B). “Q” represents quercetin and “I”**

58 **represents luteolin (internal standard).**

59

60

61



62


63 **Figure S5. Enzyme activity in quercetin-3'-glucuronidation by UGT1A9\*N-HA,**

64 **UGT1A9\*N-CFP, and UGT1A9\*N-CFP+UGT1A9\*N-HA. Data are presented as mean  $\pm$**

65 **SD of three independent determinations, and the asterisks indicate differences that are**

66 **statistically significant (\*\* $P < 0.0001$ , \*\* $P < 0.005$ , \* $P < 0.05$ ).**

67



68  
69  
70  
71  
72  
73

Figure S6. Structure-based sequence alignment of UGT1A1\*1 and UGT1A1\*1b. The secondary structure elements observed in the UGT1A1 model structure are shown above the alignment<sup>1</sup>. The signal peptide is boxed. This figure was produced with END script<sup>2</sup>.

74

**Table S1. Kinetic parameters for quercetin-3-glucuronide by UGT1A9 single expression systems.**

1A9*N-1A9*N	$K_m$ ( $\mu\text{mol/L}$ )	$K_{si}$ ( $\mu\text{mol/L}$ )	$V_{max}$ ( $\text{pmol/min/unit}$ )	$CL_{int}$ ( $\mu\text{L/min/unit}$ )	% of 1A9*1-HA	% of 1A9*1-CFP
1A9*1-HA	6.93 $\pm$ 1.52		600.4 $\pm$ 27.61	86.64	100	37.87
1A9*2-HA	3.64 $\pm$ 0.41		211.0 $\pm$ 3.5 <sup>***</sup>	57.89 <sup>*</sup>	66.82	25.30
1A9*3-HA	21.85 $\pm$ 4.80	195.7 $\pm$ 61.8	467.3 $\pm$ 57.3 <sup>*</sup>	21.39 <sup>**</sup>	24.69	9.35
1A9*5-HA	7.21 $\pm$ 1.39		34.75 $\pm$ 1.43 <sup>***</sup>	4.82 <sup>***</sup>	5.56	2.11
1A9*1-CFP	7.39 $\pm$ 0.97		1691 $\pm$ 44.0	228.8	264.1	100
1A9*2-CFP	21.02 $\pm$ 6.99	233.0 $\pm$ 120.4	175.5 $\pm$ 31.8 <sup>###</sup>	8.35 <sup>###</sup>	9.64	3.65
1A9*3-CFP	34.39 $\pm$ 7.55	139.5 $\pm$ 40.2	688.3 $\pm$ 96.1 <sup>###</sup>	20.01 <sup>###</sup>	23.10	8.75
1A9*5-CFP	34.65 $\pm$ 9.19	211.5 $\pm$ 87.7	448.7 $\pm$ 73.8 <sup>###</sup>	12.95 <sup>###</sup>	14.95	5.66

75 \* represents compared with UGT1A9\*1-HA, while # represents compared with UGT1A9\*1-CFP. Data are the mean  $\pm$  SD of three independent  
76 determinations, and the asterisks indicate differences that are statistically significant (<sup>\*\*\*</sup>  $P < 0.0001$ , <sup>\*\*</sup>  $P < 0.005$ , <sup>\*</sup>  $P < 0.05$ ; <sup>###</sup>  $P < 0.0001$ , <sup>#</sup>  $P < 0.05$ ).

77



**Table S2. Kinetic parameters for quercetin-3-glucuronide by UGT1A9 double expression systems.**

1A9*N-1A9*N	$K_m$ ( $\mu\text{mol/L}$ )	$K_{si}$ ( $\mu\text{mol/L}$ )	$V_{max}$ ( $\text{pmol/min/unit}$ )	$CL_{int}$ ( $\mu\text{L/min/unit}$ )	% of 1A9*1-HA	% of 1A9*1-CFP
1A9*1-CFP+1A9*2-HA	$2.09 \pm 0.28$		$743.7 \pm 10.9$	$356.0^{***}$	410.9	155.6
1A9*1-CFP+1A9*3-HA	$5.28 \pm 0.96$		$1816 \pm 57.9$	$343.9^{***}$	396.9	150.3
1A9*1-CFP+1A9*5-HA	$12.94 \pm 2.52$	$232.9 \pm 59.8$	$788.0 \pm 65.5$	$60.90^*$	70.29	26.62
1A9*2-CFP+1A9*3-HA	$11.52 \pm 1.72$	$278.8 \pm 65.3$	$475.4 \pm 32.3$	$41.27^{***}$	47.63	18.04
1A9*2-CFP+1A9*5-HA	$13.83 \pm 2.22$	$263.0 \pm 66.0$	$227.4 \pm 17.6$	$16.44^{**}$	18.98	7.19
1A9*3-CFP+1A9*5-HA	$8.23 \pm 1.25$		$278.3 \pm 9.4$	$33.8^*$	39.01	14.77

79 \* represents the  $CL_{int}$  of double expression compared with that of the single expression with the two single expression plus together in the  
80 bracket. Data are the mean  $\pm$  SD of three independent determinations, and the asterisks indicate differences that are statistically significant  
81 ( $^{***}P<0.0001$ ,  $^{**}P<0.005$ ,  $^*P<0.05$ ).

82 **Table S3. Plasmid constructs used for FRET analysis and co-immunoprecipitation test.**

	pFastBac1-UGT1A-CFP plasmids	pFastBac1- UGT1A -YFP plasmids	pFastBac1- UGT1A -HA plasmids
1	<i>UGT1A 1-CFP</i>	<i>UGT1A 1-YFP</i>	<i>UGT1A 1-HA</i>
2	<i>UGT1A 1*1b-CFP</i>	<i>UGT1A 1*1b -YFP</i>	<i>UGT1A 1*1b -HA</i>
3	<i>UGT1A 9*1-CFP</i>	<i>UGT1A 9*1-YFP</i>	<i>UGT1A 9*1-HA</i>
4	<i>UGT1A 9*2-CFP</i>	<i>UGT1A 9*2-YFP</i>	<i>UGT1A 9*2-HA</i>
5	<i>UGT1A 9*3-CFP</i>	<i>UGT1A 9*3-YFP</i>	<i>UGT1A 9*3-HA</i>
6	<i>UGT1A 9*5-CFP</i>	<i>UGT1A 9*5-YFP</i>	<i>UGT1A 9*5-HA</i>

83

84

85 **References**

- 86 1. Laakkonen, L. & Finel, M. A molecular model of the human  
87 UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions  
88 between different parts of the enzyme. *Mol. Pharmacol.* **77**, 931-939 (2010).  
89 2. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new  
90 ENDscript server. *Nucleic Acids Res.* **42**(Web Server issue), W320-324(2014).